Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Advertisement